Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / NS Pharma, Inc.

Clinicaltrial registered17 Nov 2026

NS Pharma, Inc.

17 Nov 2026: Trial registered · A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular Dystrophy. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
17 Nov 2026
Title
A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular Dystrophy
Conditions
Duchenne Muscular Dystrophy, Exon 44, DMD
Phase
Phase 2
Study Type
Interventional
Status
Enrolling By Invitation
Countries
United States, Australia, Canada, Japan, New Zealand, South Korea, Turkey (Türkiye)
Country
United States
Reference
NCT07943598
Location
United States, Australia, Canada
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at NS Pharma, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from United States

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.